Sarah E. Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah E. Taylor has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
- Paniti Sukumvanich
Department of Gynecologic Oncology, UPMC Magee Women's Hospital, Pittsburgh, PA
75 shared publications - Francesmary Modugno
Department of Obstetrics, Gynecology, and Reproductive Sciences University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
74 shared publications - Adelyn Bolithon
School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, Australia. 4
73 shared publications - Ahwan Pandey
Peter MacCallum Cancer Centre, Melbourne, Australia
73 shared publications - Aleksandra Gentry-Maharaj
Department of Women’s Cancer, Institute for Women’s Health, University College London, London, UK
73 shared publications - Alexander Hein
Department of Gynecology and Obstetrics, University Breast Center for Fran-conia, Erlangen University Hospital, Friedrich-Alexander University Erlangen-N€ urnberg, Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany
73 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
CT ‐Derived Body Composition Enhances Risk Prediction for Early Progression and Platinum Resistance in High‐Grade Serous Ovarian Cancer
Background: Patients with high‐grade serous ovarian cancer (HGSOC) who develop resistance to platinum‐based chemotherapy experience significantly poorer outcomes and shorter progression‐free survival (PFS). This study evaluates whether pretreatment CT‐based abdominal body composition is associated with platinum resistance and PFS, and whether its incorporation alongside clinical variables improves prognostic model performance. Methods: This retrospective study included 321 patients with HGSOC (mean age 65 ± 10 years; 28.0% platinum‐resistant) treated with platinum‐based chemotherapy between 2011 and 2023. Deep learning algorithms quantified abdominal body composition features from pretreatment CT scans, including skeletal muscle, bone, subcutaneous (SAT), visceral (VAT), and intramuscular (IMAT) adipose tissues. Platinum resistance, defined as disease progression during therapy or within 6 months of the final infusion, was the primary outcome. PFS was analyzed as a secondary outcome using Cox proportional hazards modeling. Analyses were stratified by chemotherapy sequence (neoadjuvant vs. adjuvant). Survival models incorporating clinical and CT‐derived features were evaluated using 10‐fold cross‐validated time‐dependent AUC over a 5‐year follow‐up window to predict PFS. External validation was partially performed in an independent cohort of 58 patients with HGSOC. Results: Increased SAT and IMAT and decreased skeletal muscle density were independently associated with platinum resistance, with high SAT remaining significant in both the internal and external cohorts ( p < 0.05). High adiposity and low muscle density were similarly associated with shorter PFS. Survival models combining clinical and CT‐derived features consistently outperformed clinical‐only models across all evaluated model classes. The Elastic Net Cox regression model incorporating both feature sets achieved the highest AUC of 0.704 (95% CI: 0.660–0.748). Conclusions: Pretreatment CT‐derived abdominal body composition is independently associated with platinum resistance and PFS in HGSOC, and its incorporation into predictive clinical models improves discrimination. Body composition assessment may help identify patients at increased risk of platinum resistance and early disease progression.
- 5 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessCT ‐Derived Body Composition Enhances Risk Prediction for Early Progression and Platinum Resistance in High‐Grade Serous Ovarian Cancer
Background: Patients with high‐grade serous ovarian cancer (HGSOC) who develop resistance to platinum‐based chemotherapy experience significantly poorer outcomes and shorter progression‐free survival (PFS). This study evaluates whether pretreatment CT‐based abdominal body composition is associated with platinum resistance and PFS, and whether its incorporation alongside clinical variables improves prognostic model performance. Methods: This retrospective study included 321 patients with HGSOC (mean age 65 ± 10 years; 28.0% platinum‐resistant) treated with platinum‐based chemotherapy between 2011 and 2023. Deep learning algorithms quantified abdominal body composition features from pretreatment CT scans, including skeletal muscle, bone, subcutaneous (SAT), visceral (VAT), and intramuscular (IMAT) adipose tissues. Platinum resistance, defined as disease progression during therapy or within 6 months of the final infusion, was the primary outcome. PFS was analyzed as a secondary outcome using Cox proportional hazards modeling. Analyses were stratified by chemotherapy sequence (neoadjuvant vs. adjuvant). Survival models incorporating clinical and CT‐derived features were evaluated using 10‐fold cross‐validated time‐dependent AUC over a 5‐year follow‐up window to predict PFS. External validation was partially performed in an independent cohort of 58 patients with HGSOC. Results: Increased SAT and IMAT and decreased skeletal muscle density were independently associated with platinum resistance, with high SAT remaining significant in both the internal and external cohorts ( p < 0.05). High adiposity and low muscle density were similarly associated with shorter PFS. Survival models combining clinical and CT‐derived features consistently outperformed clinical‐only models across all evaluated model classes. The Elastic Net Cox regression model incorporating both feature sets achieved the highest AUC of 0.704 (95% CI: 0.660–0.748). Conclusions: Pretreatment CT‐derived abdominal body composition is independently associated with platinum resistance and PFS in HGSOC, and its incorporation into predictive clinical models improves discrimination. Body composition assessment may help identify patients at increased risk of platinum resistance and early disease progression.
- 10 March 2026
- Published by Elsevier in Brachytherapy
- Vol. 25 (4) , 616-623
What is the optimal fractionation for image-based high-dose-rate brachytherapy boost in medically inoperable endometrial cancer: 4 versus 5 fractions?
- 10 March 2026
- Published by Elsevier in Brachytherapy
- Vol. 25 (4) , 616-623
What is the optimal fractionation for image-based high-dose-rate brachytherapy boost in medically inoperable endometrial cancer: 4 versus 5 fractions?
- Open Access
Prognostic Value of Lymphoid Infiltration and Aggregation in Cervical Cancer
Background/objectives: Understanding the immune landscape in cervical cancer is critical to the development of improved therapeutics. This study investigated the immune microenvironment in early-stage cervical cancer with a focus on B and T cell immune aggregates, i.e., lymphoid aggregates (LAs) and tertiary lymphoid structures (TLSs). Methods: Using multispectral imaging, we interrogated a cohort of patients with clinical stage I squamous or adenocarcinoma of the cervix with a focus on T and B cell spatial location and organization. Despite early-stage disease, recurrence was common at 37%, highlighting the need to identify patients at high risk for recurrence. Results: We demonstrated that high CD8+ T cell infiltration correlated significantly with improved overall survival (OS), particularly in patients with adenocarcinoma histology. CD8+ T cells colocalized with B cells, suggesting the formation of a more sophisticated cellular neighborhood, i.e., TLS, which has prognostic benefit in other solid tumors. CXCL13, a chemokine associated with TLS formation, correlated with improved recurrence-free survival. The combination of high CXCL13 and lymphoid structures correlated with improved OS. However, most immune structures in cervical cancer were lymphoid aggregates (LAs) that lack features of more developed TLS, such as high endothelial venules (HEVs) and germinal centers (GCs), highlighting a lack of full immune activation in this microenvironment. Validation in The Cancer Genome Atlas (TCGA) cohort illustrated similar trends in survival. Conclusions: Collectively, this work demonstrates the prognostic significance of immune infiltration and eventual TLS induction in early cervical cancer and presents potential future therapeutic targets.
Open AccessPrognostic Value of Lymphoid Infiltration and Aggregation in Cervical Cancer
Background/objectives: Understanding the immune landscape in cervical cancer is critical to the development of improved therapeutics. This study investigated the immune microenvironment in early-stage cervical cancer with a focus on B and T cell immune aggregates, i.e., lymphoid aggregates (LAs) and tertiary lymphoid structures (TLSs). Methods: Using multispectral imaging, we interrogated a cohort of patients with clinical stage I squamous or adenocarcinoma of the cervix with a focus on T and B cell spatial location and organization. Despite early-stage disease, recurrence was common at 37%, highlighting the need to identify patients at high risk for recurrence. Results: We demonstrated that high CD8+ T cell infiltration correlated significantly with improved overall survival (OS), particularly in patients with adenocarcinoma histology. CD8+ T cells colocalized with B cells, suggesting the formation of a more sophisticated cellular neighborhood, i.e., TLS, which has prognostic benefit in other solid tumors. CXCL13, a chemokine associated with TLS formation, correlated with improved recurrence-free survival. The combination of high CXCL13 and lymphoid structures correlated with improved OS. However, most immune structures in cervical cancer were lymphoid aggregates (LAs) that lack features of more developed TLS, such as high endothelial venules (HEVs) and germinal centers (GCs), highlighting a lack of full immune activation in this microenvironment. Validation in The Cancer Genome Atlas (TCGA) cohort illustrated similar trends in survival. Conclusions: Collectively, this work demonstrates the prognostic significance of immune infiltration and eventual TLS induction in early cervical cancer and presents potential future therapeutic targets.
- 2 June 2025
- Published by Elsevier in Cancer Epidemiology
- Vol. 97, 102854
Association of health care policy and trends in cancer screening during the COVID-19 pandemic
- 2 June 2025
- Published by Elsevier in Cancer Epidemiology
- Vol. 97, 102854
Association of health care policy and trends in cancer screening during the COVID-19 pandemic
- 1 May 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , 495-503
Twice daily template-based interstitial brachytherapy for gynecologic cancers: What is the optimal dose?
- 1 May 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , 495-503
Twice daily template-based interstitial brachytherapy for gynecologic cancers: What is the optimal dose?
- Open Access
Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma
Objective: Clear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, but up to 30% of low-stage cases relapse within five years. The benefit of adjuvant chemotherapy for low-stage CCOC (FIGO stage IA-IC1) remains uncertain. This study aimed to identify molecular and immune markers associated with relapse in a well-characterized CCOC cohort. Methods: Using the Edinburgh Ovarian Cancer Database, we identified 85 CCOC cases. Targeted DNA sequencing assessed genomic alterations and tumour immune infiltration was evaluated using CD3 and CD8 immunohistochemistry on tissue microarrays. Tumours were stratified by stage (IA-IC1, IC2-II, III-IV), and both univariate and multivariate analysis applied for progression-free survival (PFS) included stage, age, genomic features, and immune markers. Results: Common genomic alterations included ARID1A (49%) and PIK3CA (42%) mutations, PIK3-AKT pathway perturbations (60%), and mismatch repair-related mutational signatures (25.9%). Genomic and molecular features were not significantly associated with tumour stage; however, low-stage tumours (IA-IC1) were enriched in CD3+ (40% cases) and CD8+ (29% cases) tumour-infiltrating lymphocytes (TILs) compared to higher-stage tumours (IC2-II: 13%/7%; III-IV: 9%/0% cases). In univariate analysis, low CD3+ TIL levels were significantly associated with reduced progression-free survival (HR = 4.4, P = 0.042, 95% CI 1.1-18). ARID1A wild-type status was linked to poorer PFS but only in low-stage tumours HR = 7.2, P = 0.088; 95% CI 0.74-72). Notably, the combination of ARID1A wild-type status and CD3+ depletion identified a high-risk subgroup among low-stage CCOC cases (HR = 11.7, P = 0.050; 95% CI 1-138), highlighting potential as a composite risk marker set. Conclusions: Combined ARID1A mutation and low CD3+ve TIL levels are suggestive of higher recurrence risk in low-stage CCOC patients. These findings support further investigation of targeted therapies or immune checkpoint inhibitors in larger CCOC cohorts. Highlights: We report a well-characterized CCOC cohort with rich clinical, genomic and molecular data. Common mutations included ARID1A (49%) and PIK3CA (42%), with MSI in 9%, showing no significant enrichment across tumour stages. Low-stage CCOC has higher levels of CD3+ & CD8+ tumour infiltrating leukocytes than in advanced-stage disease. ARID1A wild-type tumours with CD3+ TIL depletion represent a high-risk subgroup of low-stage CCOC. Findings support further study and highlight potential markers for recurrence risk.
Open AccessCombined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma
Objective: Clear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, but up to 30% of low-stage cases relapse within five years. The benefit of adjuvant chemotherapy for low-stage CCOC (FIGO stage IA-IC1) remains uncertain. This study aimed to identify molecular and immune markers associated with relapse in a well-characterized CCOC cohort. Methods: Using the Edinburgh Ovarian Cancer Database, we identified 85 CCOC cases. Targeted DNA sequencing assessed genomic alterations and tumour immune infiltration was evaluated using CD3 and CD8 immunohistochemistry on tissue microarrays. Tumours were stratified by stage (IA-IC1, IC2-II, III-IV), and both univariate and multivariate analysis applied for progression-free survival (PFS) included stage, age, genomic features, and immune markers. Results: Common genomic alterations included ARID1A (49%) and PIK3CA (42%) mutations, PIK3-AKT pathway perturbations (60%), and mismatch repair-related mutational signatures (25.9%). Genomic and molecular features were not significantly associated with tumour stage; however, low-stage tumours (IA-IC1) were enriched in CD3+ (40% cases) and CD8+ (29% cases) tumour-infiltrating lymphocytes (TILs) compared to higher-stage tumours (IC2-II: 13%/7%; III-IV: 9%/0% cases). In univariate analysis, low CD3+ TIL levels were significantly associated with reduced progression-free survival (HR = 4.4, P = 0.042, 95% CI 1.1-18). ARID1A wild-type status was linked to poorer PFS but only in low-stage tumours HR = 7.2, P = 0.088; 95% CI 0.74-72). Notably, the combination of ARID1A wild-type status and CD3+ depletion identified a high-risk subgroup among low-stage CCOC cases (HR = 11.7, P = 0.050; 95% CI 1-138), highlighting potential as a composite risk marker set. Conclusions: Combined ARID1A mutation and low CD3+ve TIL levels are suggestive of higher recurrence risk in low-stage CCOC patients. These findings support further investigation of targeted therapies or immune checkpoint inhibitors in larger CCOC cohorts. Highlights: We report a well-characterized CCOC cohort with rich clinical, genomic and molecular data. Common mutations included ARID1A (49%) and PIK3CA (42%), with MSI in 9%, showing no significant enrichment across tumour stages. Low-stage CCOC has higher levels of CD3+ & CD8+ tumour infiltrating leukocytes than in advanced-stage disease. ARID1A wild-type tumours with CD3+ TIL depletion represent a high-risk subgroup of low-stage CCOC. Findings support further study and highlight potential markers for recurrence risk.
- 14 December 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-12
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
Background The addition of IV triapine to chemoradiation appeared active in phase I and II studies but drug delivery is cumbersome. We examined PO triapine with cisplatin chemoradiation. Methods We implemented a 3 + 3 design for PO triapine dose escalation with expansion, starting at 100 mg, five days a week for five weeks while receiving radiation with weekly IV cisplatin for locally advanced cervical or vaginal cancer. Maximum tolerated dose (MTD), dose limiting toxicity (DLT), adverse events, pharmacokinetics (PK), pharmacodynamics (PD), and metabolic complete response (mCR) were assessed. Results 19/21 patients were DLT evaluable. DLTs included grade 4 neutropenia (n = 2), leukopenia (n = 2), lymphopenia (n = 2), and hypokalemia (n = 1). Grade 3 toxicities at least possibly related were as expected for cisplatin chemoradiation: lymphopenia (n = 12), anemia (n = 10), neutropenia (n = 4), leukopenia (n = 8), decreased platelets (n = 2), hypertension (n = 1), and hyponatremia (n = 1). MTD and RP2D were established at 100 mg. 8/13 evaluable patients had a mCR. Triapine had a bioavailability of 59%. Methemoglobin levels correlated with triapine exposure. Smoking almost doubled CYP1A2 mediated triapine clearance. Conclusions Oral triapine is safe when given with cisplatin chemoradiation, convenient, bioavailable. Exposure is negatively impacted by smoking, and methemoglobin is a biomarker of exposure. Clinical trial registration NCT02595879.
- 14 December 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-12
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
Background The addition of IV triapine to chemoradiation appeared active in phase I and II studies but drug delivery is cumbersome. We examined PO triapine with cisplatin chemoradiation. Methods We implemented a 3 + 3 design for PO triapine dose escalation with expansion, starting at 100 mg, five days a week for five weeks while receiving radiation with weekly IV cisplatin for locally advanced cervical or vaginal cancer. Maximum tolerated dose (MTD), dose limiting toxicity (DLT), adverse events, pharmacokinetics (PK), pharmacodynamics (PD), and metabolic complete response (mCR) were assessed. Results 19/21 patients were DLT evaluable. DLTs included grade 4 neutropenia (n = 2), leukopenia (n = 2), lymphopenia (n = 2), and hypokalemia (n = 1). Grade 3 toxicities at least possibly related were as expected for cisplatin chemoradiation: lymphopenia (n = 12), anemia (n = 10), neutropenia (n = 4), leukopenia (n = 8), decreased platelets (n = 2), hypertension (n = 1), and hyponatremia (n = 1). MTD and RP2D were established at 100 mg. 8/13 evaluable patients had a mCR. Triapine had a bioavailability of 59%. Methemoglobin levels correlated with triapine exposure. Smoking almost doubled CYP1A2 mediated triapine clearance. Conclusions Oral triapine is safe when given with cisplatin chemoradiation, convenient, bioavailable. Exposure is negatively impacted by smoking, and methemoglobin is a biomarker of exposure. Clinical trial registration NCT02595879.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Figure 3 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples (27) are shown, as well as alterations in immune genes and CCNE1. Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS < 2 years), tumor CHORD (41) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status (BRCA1-type HRD; BRCA2-type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples (27) are shown, as well as alterations in immune genes and CCNE1. Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS < 2 years), tumor CHORD (41) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status (BRCA1-type HRD; BRCA2-type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S12. Clinical characteristics of patients with HGSC.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S12. Clinical characteristics of patients with HGSC.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S17 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S17 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.